BPC TB 5 Beverly Hills Rejuvenation Center The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and FDA Peptide Reclassification 2026: What It Means for Providers In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for Early evidence suggests BPC 157 repairs tissue rather than just dulling symptoms. To read more, tap the link in bio.